SpectraCure

SpectraCure is a Swedish medical technology company based in Lund that develops a proprietary photodynamic therapy system for treating localized prostate cancer. Its platform combines a laser-based treatment device, a photosensitive drug, and patented dose-control software under the Q-PRO and IDOSE® names, with the same core technology designed to be adaptable to other solid tumors.

— SpectraCure
%
Treatment system hardware40% Laser-based medical device components used to deliver interstitial PDT treatment.
Control software20% Patented IDOSE® software that manages light dose and treatment precision.
Clinical development services25% Clinical studies and evidence generation for prostate cancer indications.
Industrialization and manufacturing preparation15% Work to enable future series production and product launch.

SpectraCure’s direct customers are not end patients but healthcare providers, clinical investigators, and ultimately...

  • Clinical investigators and reference clinicsprimary

    They run the prostate cancer studies and generate the clinical evidence needed for approval and adoption.

  • Hospitals and cancer centersprimary

    Future buyers of the Q-PRO® system for focal treatment of localized prostate cancer.

  • Medical technology partnerssecondary

    They support product development, industrialization, and future manufacturing readiness.

  • Licensing and commercialization partnerssecondary

    Potential partners for broader market access and technology monetization.

SpectraCure is headquartered in Lund, Sweden, and its development work is anchored there...

  • •Headquartered in Lund, Sweden
  • •Clinical studies run in North America and Europe
  • •Initial market focus is North America and Europe
  • •Industrialization work involves the Netherlands and Switzerland
  • •Future commercialization depends on regulatory access in target markets

SpectraCure’s strategy is to build clinical evidence for Q-PRO® in recurrent and primary localized prostate cancer,...

01
Clinical validation in prostate cancershort-term

Approval and adoption depend on demonstrating safety and efficacy in well-run studies.

02
Regulatory pathway in target marketsmedium-term

Commercial launch requires market authorization in North America and Europe.

03
Industrialization and manufacturabilitymedium-term

The system must be ready for series production before commercialization.

04
Platform expansion beyond prostate cancerlong-term

The same PDT approach may be adapted to other solid tumors over time.

SpectraCure’s main risks are tied to clinical development, regulatory approval, and the ability to secure...

critical

Clinical development risk

The business depends on proving that Q-PRO® is safe and effective in patient studies.

Scope
Recurrent and primary localized prostate cancer trials
Materiality
high
high

Regulatory approval risk

Commercial launch cannot occur without market authorization in target regions.

Scope
North America and Europe
Materiality
high
high

Licensing and commercialization risk

Future monetization may rely on licensing or partner agreements on acceptable terms.

Materiality
high
medium

Competition from alternative treatments

Other prostate cancer therapies may be more established, better funded, or easier to adopt.

Materiality
medium
medium

Partner dependency risk

Industrialization and development rely on external collaborators and reference clinics.

Materiality
medium
IFRS 15
IFRS 15 service revenue
Affects reported other operating income
Grant income recognition
Affects timing of other operating income
Related-party transactions
Affects comparability of revenue and margins
IFRS 16
IFRS 16 lease accounting
Affects operating vs financing cash flow presentation

Spectral AI, Inc.

MDAI · Surgical & Medical Instruments & Apparatus

NovoCure Ltd

NVCR · Surgical & Medical Instruments & Apparatus

Boliden

BOL.ST · Basic Materials

Loomis

LOOMIS.ST · Industrials

New Wave

NEWA-B.ST · Consumer Discretionary

Bufab

BUFAB.ST · Industrials

: 11/08/2026